A Randomized, Open-Label Study of Alternative Treatment Combinations of Dideoxycytidine (HIVID; ddC) and Zidovudine (AZT) in Patients With HIV Infection

Roche

Status and phase: Completed; Phase 3

Conditions: HIV Infections

Treatments: Drug: Zidovudine; Drug: Zalcitabine

Study type: Interventional

Funder types: Industry

Identifiers

NCT00002117

220A

NV 14257

Details and patient eligibility

About

To investigate the appropriate zalcitabine ( dideoxycytidine; ddC ) dose and zidovudine ( AZT ) schedule for use in combination therapy in patients with HIV infection.

Full description

Patients are randomized to one of four treatment arms. ddC is administered at 1 of 2 doses every 8 hours. AZT is administered at 1 of 2 doses (every 4 hours while awake or every 8 hours).

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria

Patients must have:

• HIV infection.
• CD4 count 100 - 500 cells/mm3.